文献速递基础与转化研究临床试验与 GCP

Etokimab概念验证临床试验表明IL-33在特应性皮炎发病机制中的关键作用

Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis.
PubMed 文献 · Sci Transl Med · 2019-01-01

一项首次人体2a期研究评估了抗IL-33单克隆抗体etokimab(ANB020)在12例中重度特应性皮炎成人患者中的疗效与机制。单次系统性给药后观察到快速持久的临床获益:83%达到EASI50、33%达到EASI75,第29天外周血嗜酸性粒细胞减少。屋尘螨皮肤激发后,与安慰剂相比etokimab显著减少皮肤中性粒细胞浸润,体外实验显示etokimab抑制中性粒细胞向皮肤间质液迁移,并揭示CXCR1依赖性的IL-8诱导中性粒细胞迁移效应。

要点

  • 单次etokimab给药后83%患者达到EASI50、33%达到EASI75。
  • 第29天外周血嗜酸性粒细胞减少。
  • 屋尘螨激发后皮肤中性粒细胞浸润较安慰剂显著减少。

核心结论

  • 人体内研究结果证实IL-33在调控皮肤炎症级联反应中发挥上游作用,并定义了IL-33抑制在包括特应性皮炎在内的人类疾病中的治疗潜力。

研究设计与样本

  • 首次人体2a期研究,纳入12例中重度特应性皮炎成人患者,单次系统性给予抗IL-33单克隆抗体etokimab(ANB020)。

主要发现

  • 83%患者达到EASI50,33%患者达到EASI75。
  • 第29天外周血嗜酸性粒细胞减少。
  • 屋尘螨皮肤激发后,etokimab组皮肤中性粒细胞浸润较安慰剂组显著减少。
  • 体外实验显示etokimab抑制中性粒细胞向皮肤间质液迁移,并揭示CXCR1依赖性的IL-8诱导中性粒细胞迁移效应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted inhibition of cytokine pathways provides opportunities to understand fundamental biology in vivo in humans. The IL-33 pathway has been implicated in the pathogenesis of atopy through genetic and functional associations. We investigated the role of IL-33 inhibition in a first-in-class phase 2a study of etokimab (ANB020), an IgG1 anti-IL-33 monoclonal antibody, in patients with atopic dermatitis (AD). Twelve adult patients with moderate to severe AD received a single systemic administration of etokimab. Rapid and sustained clinical benefit was observed, with 83% achieving Eczema Area and Severity Index 50 (EASI50), and 33% EASI75, with reduction in peripheral eosinophils at day 29 after administration. We noted significant reduction in skin neutrophil infiltration after etokimab compared with placebo upon skin challenge with house dust mite, reactivity to which has been implicated in the pathogenesis of AD. We showed that etokimab also inhibited neutrophil migration to skin interstitial fluid in vitro. Besides direct effects on neutrophil migration, etokimab revealed additional unexpected CXCR1-dependent effects on IL-8-induced neutrophil migration. These human in vivo findings confirm an IL-33 upstream role in modulating skin inflammatory cascades and define the therapeutic potential for IL-33 inhibition in human diseases, including AD.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019. PMID: 31645451. doi:10.1126/scitranslmed.aax2945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。